YM has received per diem, including speaking fees, from Novartis Pharma, AbbVie, Nippon Shinyaku, Astellas Pharma, SymBio Pharmaceuticals, and Sumitomo Pharma, and has received research funding from Asahi Kasei Pharma and Chugai Pharmaceutical.